Identification and characterization of an Aβ oligomer precipitating peptide that may be useful to explore gene therapeutic approaches to alzheimer fisease

Rejuvenation Research

Volumn 15, Issue 2, 2012, Pages 144-147

  Funke, Susanne Aileen ^a   Liu, Hongmei ^a   Sehl, Torsten ^a   Bartnik, Dirk ^a   Brener, Oleksandr ^a,b   Nagel Steger, Luitgard ^a,b   Wiesehan, Katja ^a   Willbold, Dieter ^a,b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BINDING PROTEIN; OLIGOMER; PROTEIN L3; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; GENE THERAPY; IN VITRO STUDY; MOUSE; NEUROBLASTOMA CELL; NEUROPATHOLOGY; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENILE PLAQUE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE, TUMOR; CENTRIFUGATION, DENSITY GRADIENT; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; MICE; NEPHELOMETRY AND TURBIDIMETRY; NEURONS; PEPTIDES; SEQUENCE ANALYSIS, DNA; THIAZOLES;

EID: 84860275678     PISSN: 15491684     EISSN: 15578577     Source Type: Journal    
DOI: 10.1089/rej.2011.1262     Document Type: Article

References (15)

1. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimer's amyloid betapeptide. Nat Rev Mol Cell Biol 2007;8:101-112.
2. Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 1992;256:184-185.
3. Selkoe DJ. The molecular pathology of Alzheimer's disease. Neuron 1991;6:487-498.
4. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropatholog 2010;119:523-541.
5. LaFerla FM, Green KN, Oddo S. Intracellular amyloidbeta in Alzheimer's disease. Nat Rev Neurosci 2007;8: 499-509.
6. Bartnik D, Funke SA, Andrei-Selmer LC, Bacher M, Dodel R, Willbold D. Differently selected d-enantiomeric peptides act on different Abeta species. Rejuvenation Res 2010;13: 302-305.
7. Funke SA, van Groen T, Kadish I, Bartnik D, Nagel-Steger L, Brener O, Sehl T, Batra-Safferling R, Moriscot C, Schoehn G, Horn AHC, MÜ ller-Schiffmann A, Korth C, Sticht H, Willbold D. Oral treatment with the D-enantiomeric peptide D3 improves pathology and behavior of Alzheimer's disease transgenic mice. ACS Chem Neurosci 2010;1:639-648.
8. Muller-Schiffmann A, Marz-Berberich J, Andreyeva A, Ronicke R, Bartnik D, Brener O, Kutzsche J, Horn AH, Hellmert M, Polkowska J, Gottmann K, Reymann KG, Funke SA, Nagel-Steger L, Moriscot C, Schoehn G, Sticht H, Willbold D, Schrader T, Korth C. Combining independent drug classes into superior, synergistically acting hybrid molecules. Angew Chem Int Ed Engl 2010;49:8743-8746.
9. van Groen T, Kadish I, Wiesehan K, Funke SA, Willbold D. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models. ChemMedChem 2009;4:276-282.
10. van Groen T, Wiesehan K, Funke SA, Kadish I, Nagel-Steger L, Willbold D. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, a D-enantiomeric peptide identified by mirror image phage display. Chem- MedChem 2008;3:1848-1852.
11. Soderberg L, Dahlqvist C, Kakuyama H, Thyberg J, Ito A, Winblad B, Naslund J, Tjernberg LO. Collagenous Alzheimer amyloid plaque component assembles amyloid fibrils into protease resistant aggregates. FEBS J 2005;272:2231-2236.
12. Bendtsen JD, Nielsen H, von Heijne G, Brunak S. Improved prediction of signal peptides: SignalP 3.0. J Mol Biol 2004;340:783-795.
13. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, Singh S. Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol. 2005;151:229-238.
14. Harper JD, Lansbury PT, Jr. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 1997;66:385-407.
15. Fauchere JL, Thurieau, C. Evaluation of the stability of peptides and pseudopeptides as a tool in peptide drug design. Adv Drug Res 1992;23:127-159.